AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics Announces CEO Transition

17 May 2022 15:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference

10 May 2022 07:00:03 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

03 May 2022 16:40:58 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8:00 a.m. ET

18 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital

13 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

12 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis

17 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Full Year 2021 Results Exceeding Revenue and EBITDA Guidance

08 Mar 2022 15:56:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China

03 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

28 Feb 2022 19:33:43 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

25 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film

24 Feb 2022 20:26:14 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Fourth Quarter and Year End 2021 Financial Results and Recent Business Highlights on March 8 and Host Conference Call on March 9 at 8:00 a.m. ET

22 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

07 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film

20 Dec 2021 21:49:09 By Nasdaq GlobeNewswire

Aquestive Therapeutics Added to NASDAQ Biotechnology Index

17 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

17 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance

02 Nov 2021 15:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergic Reactions

25 Oct 2021 07:31:04 By Nasdaq GlobeNewswire